Erasca, Inc. — Form 10-Q Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. Its pipeline included 11 programs, with ERAS-007 and ERAS-601 in clinical development and other programs in preclinical or discovery stages. The filing covers the three and six months ended June 30, 2021, with comparisons to the corresponding 2020 periods.
The company had no approved products and generated no revenue. It expects product revenue, if any, to be several years away and dependent on successful clinical development and regulatory approval.
Financial condition and key metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $17.6 million | $29.8 million |
| In-process R&D expense | $5.5 million | $9.2 million |
| General and administrative expense | $5.1 million | $8.8 million |
| Total operating expenses | $28.2 million | $47.8 million |
| Operating loss | $28.2 million | $47.8 million |
| Net loss | $28.2 million | $46.2 million |
| Net loss per share, basic and diluted | $1.20 | $2.02 |
| Net cash used in operating activities | Not separately provided | $33.9 million |
Gross loss and operating margins are not meaningful because the company had no revenue. The net loss increased from $5.5 million to $28.2 million year over year in the second quarter and from $29.1 million to $46.2 million for the six-month period.
At June 30, 2021, cash and cash equivalents were $156.4 million, short-term investments were $37.3 million, and long-term investments were $5.0 million, for approximately $198.7 million of cash, cash equivalents and investments. Restricted cash was $0.4 million. Total assets were $210.4 million, total liabilities were $19.6 million, and accumulated deficit was $161.6 million.
The filing does not report outstanding debt. Current liabilities were $17.9 million, including $15.5 million of accrued expenses and other current liabilities. Operating lease liabilities totaled $2.6 million, and the company had approximately $51.6 million of commitments related to a new facility lease that had not commenced as of June 30, 2021.
Material changes versus the prior comparable period
- Research and development expense increased by $11.7 million, or approximately 200%, in the second quarter and by $19.4 million for the six-month period, primarily due to increased clinical and preclinical activity, personnel costs, outsourced services and consulting.
- General and administrative expense increased by $3.7 million in the second quarter and $5.7 million for the six-month period, driven primarily by higher personnel, legal and audit costs.
- Second-quarter in-process R&D expense of $5.5 million reflected the issuance of 944,945 common shares to the Regents of the University of California in connection with an amendment to the UCSF license agreement.
- Six-month in-process R&D expense included the UCSF license amendment and the Emerge Life Sciences asset acquisition. The 2020 comparable period included $12.0 million of NiKang payments and $5.7 million related to the Katmai license.
- Net cash used in operating activities increased to $33.9 million from $12.1 million. Financing provided $120.7 million, primarily from the January 2021 issuance of Series B-2 preferred stock.
- The preferred stock purchase right liability was settled in January 2021. Accordingly, the second quarter had no related fair-value gain, compared with a $1.8 million gain in the second quarter of 2020.
- Common stock outstanding increased to 24.4 million shares at June 30, 2021 from 21.9 million at December 31, 2020, excluding shares issuable upon preferred-stock conversion and other potentially dilutive securities.
Guidance, outlook, commentary and risks
Management expected research and development and general and administrative expenses, operating losses and cash needs to increase substantially as clinical trials, preclinical programs, manufacturing activities, personnel and public-company costs expanded. Based on the filing’s operating plan, cash, cash equivalents and investments at June 30, 2021, together with subsequent IPO proceeds, were expected to fund operations for at least 24 months. The company stated that it would likely require additional capital in the future and had no other committed sources of capital.
Clinical milestones included dosing the first patient in the HERKULES-1 trial in May 2021, planned initiation of HERKULES-2 in the third quarter of 2021, HERKULES-3 in the second half of 2021 and HERKULES-4 in the first quarter of 2022. The company expected to file an IND for ERAS-801 in the first quarter of 2022 and for ERAS-3490 in the second half of 2022.
After quarter-end, the company completed its IPO on July 20, 2021, selling 21,562,500 shares at $16.00 per share for net proceeds of $317.7 million. All outstanding convertible preferred stock converted into 71,263,685 common shares. In August 2021, the company paid the Regents $1.7 million following achievement of a corporate milestone.
- The company has a limited operating history, recurring losses, negative operating cash flow and no product revenue.
- Clinical and preclinical programs may fail, be delayed, face enrollment or safety issues, or fail to obtain regulatory approval.
- ERAS-007 and ERAS-601 may produce class-related toxicities, including ophthalmic, skin, gastrointestinal and hematologic events. The filing reported one dose-limiting toxicity and three drug-related serious adverse events in the FLAGSHP-1 trial as of June 1, 2021.
- The company relies on third parties for clinical research, manufacturing, testing, packaging and distribution, without redundant supply arrangements for all required materials.
- COVID-19 could disrupt clinical enrollment, research, manufacturing, supply chains and regulatory activities, although no material disruption had occurred as of the filing.
- The company is exposed to intellectual-property license obligations, milestone payments, royalties, diligence requirements and termination risks. Potential future payments include up to $90.0 million under the Asana agreements, as well as additional milestones and royalties under other licenses.
- The company faces competition, regulatory uncertainty, potential product liability, data-security risks, dilution from future financing and significant stock-price volatility.
Important facts for investors to verify
- Reconcile the June 30 cash and investment balance with the post-quarter-end IPO proceeds and the company’s stated 24-month funding outlook.
- Track clinical enrollment, safety findings and proof-of-concept data for ERAS-007, ERAS-601 and the HERKULES trials.
- Verify the timing and amount of future license, development and regulatory milestone obligations.
- Assess the impact of the preferred-stock conversion, IPO issuance, option overhang and other potential dilution.
- Monitor the $51.6 million facility commitment and future operating lease cash requirements.
- Confirm that no revenue, profitability or positive operating cash flow is expected in the near term absent successful regulatory approvals and commercialization.